Praxis Precision Medicines saw its stock soar by 100% on Thursday, following encouraging late-stage results for its experimental essential tremor treatment, ulixacaltamide. The Boston-based biotech ...
Essential tremor impacts 7 million Americans who navigate their condition without a targeted treatment. Finally, that’s about ...
Shares of Praxis Precision Medicines hit their highest intraday level since March 2022 Biopharmaceutical company Praxis Precision Medicines says that Phase 3 trials of its ulixacaltamide drug have ...
Shares of Praxis Precision Medicines rallied more than 200% on Thursday after the biotech said patients with a condition that causes uncontrollable shaking saw improvement on the company’s ...
Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Monday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for ulixacaltamide for essential ...
Fasikl has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Felix NeuroAI Wristband, designed to address tremor-related functional limitations in adults. Essential ...
(RTTNews) - Praxis Precision Medicines, Inc. (PRAX) on Monday said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ulixacaltamide for the treatment of patients ...
Propranolol and Primidone demonstrate efficacy in up to 70% of patients as first-line agents. MR-Guided Focused Ultrasound (MRgFUS) results in approximately 56% tremor reduction at 4 years. Deep Brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results